ACBP suppresses the proliferation, migration, and invasion of colorectal cancer via targeting Wnt/beta-catenin signaling pathway

Xin Tong,Zhuochen Zhuang,Xianjue Wang,Xiaoyu Yang,Liping Bai,Liya Su,Ping Wei,Xiulan Su
DOI: https://doi.org/10.1016/j.biopha.2020.111209
2021-05-01
Abstract:<p>Anticancer bioactive peptide (ACBP), a novel bioactive peptide isolated from spleens of goats immunized with tumor extracts in our lab, can inhibit the proliferation of CRC <em>in vitro</em> and <em>vivo</em>. However, it remains unclear how the proliferation of CRC is inhibited by ACBP at the molecular level. Here, we provide evidences showing that ACBP significantly inhibits the expression of Wnt/β-catenin related genes (<em>cyclin D1</em>, <em>met</em> and <em>c-myc</em>) through pharmacotranscriptomic and qRT-PCR analysis in CRCs. Active β-catenin, a key protein within Wnt pathway, was compromised remarkably by ACBP in three CRCs, including HCT116, RKO and HT29. Thus nuclear accumulation of active β-catenin was retarded and finally lead to the decreased expression of oncogenes <em>cyclin D1</em>, <em>met</em>, and <em>c-myc</em>. In addition, we proved that active β-catenin reduction was mainly due to the inhibition of phospho-LRP6 and stimulation of phospho-β-catenin by ACBP. Based on the detection of Met and C-Myc in CRC tumor tissue without prior radiotherapy or chemotherapy, our results demonstrated that ACBP can act as a promising anticancer agent for CRC by targeting Wnt/β-catenin pathway, especially active β-catenin.</p>
pharmacology & pharmacy,medicine, research & experimental
What problem does this paper attempt to address?